Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5][41]. Core Views - The pharmaceutical sector has shown weaker performance compared to the overall market, with a TTM P/E ratio of 38.51x, which is at the 84.35th percentile of the past five years [1][37]. - The report highlights the importance of the CXO sector, emphasizing the competitive advantages of Chinese companies in the chemical CDMO field, and suggests that the sector's valuation is expected to recover [41]. - The report recommends focusing on innovative drugs and the associated industry chain, with a notable mention of the upcoming JPM conference and the clinical progress of innovative drugs overseas [41][42]. Summary by Sections Market Performance - The overall A-share market increased by 1.17%, while the biotechnology sector declined by 0.39%. The medical services sector was the worst performer, dropping by 2.17% [1][32]. - The report notes that the largest sub-sectors by holding percentage are chemical preparations (37.5%) and other biological products (20.8%) [19]. Fund Holdings Analysis - As of Q4 2025, the total net asset value of pharmaceutical funds reached 358.4 billion, a decrease of 9.0% from the previous quarter [11]. - The report indicates that the pharmaceutical holdings of all funds accounted for 7.97%, down by 1.71 percentage points [16]. Key Company Earnings Forecasts - The report provides earnings forecasts for several key companies, all rated "Outperform": - Mindray Medical (300760.SZ): 2024A net profit of 11.67 billion [4] - WuXi AppTec (603259.SH): 2024A net profit of 9.35 billion [4] - Aier Eye Hospital (300015.SZ): 2024A net profit of 3.56 billion [4] - New Industry (300832.SZ): 2024A net profit of 1.83 billion [4] - Huatai Medical (688617.SH): 2024A net profit of 670 million [4] Investment Strategy - The report recommends a portfolio of stocks including Mindray Medical, WuXi AppTec, Aier Eye Hospital, and others, focusing on companies with strong growth potential in the innovative drug sector [42][43].

报告期内，公司聚焦主业，坚持产品创新、技术服务、国际化发展战略，推动各项业务持续稳定健康发 展。预计2025年度实现归母净利润约5.8亿元至6.1亿元，同比增长约62.55%至70.96%。 格隆汇1月26日丨大博医疗(002901.SZ)公布，预计2025年归属于上市公司股东的净利润58,000万元– 61,000万元，比上年同期增长62.55%–70.96%，扣除非经常性损益后的净利润45,500万元–48,500万元， 比上年同期增长59.42%–69.93%。 ...

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 报告期内，公司聚焦主业，坚持产品创新、技术服务、国际化发展战略，推动各项业务持续稳定健康发 展。预计 2025 年度实现归母净利润约 5.8 亿元至 6.1 亿元，同比增长约62.55%至 70.96%。 大博医疗2025年三季报显示，前三季度公司主营收入18.76亿元，同比上升22.69%；归母净利润4.25亿 元，同比上升77.03%；扣非净利润3.46亿元，同比上升63.99%；其中2025年第三季度，公司单季度主营 收入6.66亿元，同比上升17.82%；单季度归母净利润1.8亿元，同比上升77.49%；单季度扣非净利润1.23 亿元，同比上升38.44%；负债率24.53%，投资收益580.87万元，财务费用-2387.47万元，毛利率 71.23%。 证券之星消息，大博医疗发布业绩预告，预计2025年全年归属净利润盈利5.8亿元至6.1亿元。 公告中解释本次业绩变动的原因为： ...

报告期内，公司聚焦主业，坚持产品创新、技术服务、国际化发展战略，推动各项业务持续稳定健康发 展。预计 2025 年度实现归母净利润约 5.8 亿元至 6.1 亿元，同比增长约62.55%至 70.96%。 大博医疗2025年三季报显示，前三季度公司主营收入18.76亿元，同比上升22.69%；归母净利润4.25亿 元，同比上升77.03%；扣非净利润3.46亿元，同比上升63.99%；其中2025年第三季度，公司单季度主营 收入6.66亿元，同比上升17.82%；单季度归母净利润1.8亿元，同比上升77.49%；单季度扣非净利润1.23 亿元，同比上升38.44%；负债率24.53%，投资收益580.87万元，财务费用-2387.47万元，毛利率 71.23%。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 公告中解释本次业绩变动的原因为： 证券之星消息，大博医疗发布业绩预告，预计2025年全年每股收益盈利:1.43元至1.5元。 ...

智通财经APP讯，微创心通-B(02160)公布，董事会建议将公司股本按每5股每股面值0.000005美元的已 发行及未发行现有股份合并为1股每股面值0.000025美元的合并股份的基准实施股份合并。 于本公告日期，现有股份以每手买卖单位1,000股现有股份于联交所买卖。于股份合并生效后，于联交 所买卖的每手买卖单位将维持不变为1,000股合并股份。 ...

人民财讯1月26日电，大博医疗（002901）1月26日发布业绩预告，预计2025年归母净利润5.8亿元—6.1 亿元，同比增长62.55%—70.96%。 ...

（记者 曾健辉） 每经头条（nbdtoutiao）——国际金价冲破5000美元！7年涨了280%，什么时候才见顶？专家：关键还 看美元，重点关注国际货币体系、降息和科技革命 每经AI快讯，大博医疗1月26日晚间发布业绩预告，预计2025年归属于上市公司股东的净利润5.8亿元 ~6.1亿元，同比增长62.55%~70.96%；基本每股收益1.43元~1.5元。业绩变动主要原因是，报告期内， 公司聚焦主业，坚持产品创新、技术服务、国际化发展战略，推动各项业务持续稳定健康发展。预计 2025年度实现归母净利润约5.8亿元至6.1亿元，同比增长约62.55%至70.96%。 ...

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5] Core Views - The pharmaceutical sector underperformed the overall market, with a 0.39% decline in the biopharmaceutical sector compared to a 1.17% increase in the total A-share market [32] - The TTM price-to-earnings ratio for the pharmaceutical sector is 38.51x, which is at the 84.35th percentile of the historical valuation over the past five years [32][37] - The report highlights a shift in fund holdings, with a decrease in the proportion of pharmaceutical holdings in both pharmaceutical and non-pharmaceutical funds [11][16] Summary by Sections Market Performance - The overall A-share market increased by 1.17%, while the Shanghai and Shenzhen 300 index decreased by 0.62% [32] - The biopharmaceutical sector's performance was weaker than the overall market, with specific declines in chemical pharmaceuticals (-1.11%) and medical services (-2.17%) [32] Fund Holdings Analysis - As of Q4 2025, the net asset value of pharmaceutical funds reached 358.4 billion, a decrease of 9.0% from the previous quarter [11] - The proportion of pharmaceutical holdings in all funds was 7.97%, down 1.71 percentage points [16] - The largest sub-sectors by holdings were chemical preparations (37.5%) and other biological products (20.8%) [19] Company Earnings Forecasts and Ratings - Key companies such as Mindray Medical (237 billion market cap, "Outperform" rating) and WuXi AppTec (293.6 billion market cap, "Outperform" rating) are highlighted for their strong earnings forecasts [4] - The report lists several companies with projected earnings growth, including Aier Eye Hospital and New Industry, both rated "Outperform" [4] Investment Strategy - The report recommends focusing on innovative drugs and the CXO sector, emphasizing the competitive advantages of Chinese companies in the chemical CDMO space [41] - A portfolio of recommended stocks includes Mindray Medical, WuXi AppTec, and Aier Eye Hospital, among others [42][43]

Report Industry Investment Rating - Not provided in the report Core Viewpoints - The primary market issuance of Chinese offshore bonds declined last week, with 6 new bonds issued, totaling approximately $1.906 billion. The secondary market showed a slight increase, and US Treasury yields fluctuated upward [1][2][3] Summary by Directory 1. Primary Market - The issuance volume of the primary market for Chinese offshore bonds declined last week, with 6 new bonds issued, totaling approximately $1.906 billion. MTR Corporation issued two green bonds totaling A$2 billion, the largest issuance scale last week, and Shui On Land issued a $300 million bond with a coupon rate of 9.75%, the highest - priced new bond last week [7] 2. Secondary Market 2.1 Chinese US - dollar Bond Index Performance - The Chinese US - dollar bond index (Bloomberg Barclays) rose 0.15% week - on - week, and the emerging market US - dollar bond index rose 0.20%. The investment - grade index was at 203.1452, up 0.15% for the week, and the high - yield index was at 161.8156, up 0.18% for the week. The Chinese US - dollar bond return index (Markit iBoxx) rose 0.11% week - on - week, with the investment - grade return index at 244.9461, up 0.1% for the week, and the high - yield return index at 243.7889, up 0.21% for the week [9][14] 2.2 Performance of Chinese US - dollar Bond Industries - Different industries showed different trends. The telecommunications and healthcare sectors led the rise, while the real estate and non - essential consumer sectors led the decline. For example, the telecommunications sector's yield decreased by 45.5bps, and the healthcare sector's yield decreased by 40.2bps. The real estate sector's yield increased by 19.6Mbps, and the non - essential consumer sector's yield increased by 98bps [19][24] 2.3 Performance of Chinese US - dollar Bonds by Different Ratings - Investment - grade names generally rose, with the A - grade weekly yield down 5.0bps and the BBB - grade weekly yield down 2.7bps. High - yield names mostly fell, with the BB - grade yield down 6.6bps, the DD+ to NR - grade yield up about 7.9bps, and the non - rated name yield up 6.7Mbps [21] 2.4 Hot Events in the Bond Market Last Week - Fanhai Holdings failed to repay interest - bearing debts totaling 34.06 billion yuan as of December 31, 2025. Sunac China Holdings had new overdue borrowings and 19 new acts of dishonesty [25][26] 2.5 Rating Adjustments of Entities Last Week - Sichuan Huixing Industrial Investment and Development Co., Ltd.'s long - term issuer credit rating was BBB -; Qingdao Haifa Group's international long - term issuer credit rating was upgraded from A to A+; Ganzhou Urban Construction Investment Group's issuer rating was A - with a positive outlook; Moody's maintained the rating and stable outlook of Bohai Bank; Moody's adjusted the rating outlook of Yuexiu Real Estate Investment Trust Fund to stable; Moody's downgraded Wanda Commercial's family rating to Ca with a negative outlook; Fitch confirmed the long - term foreign and domestic currency issuer rating of Qingdao Huatong Group as BBB+ with a stable outlook [28][29] 3. US Treasury Bond Quotes - The report provides quotes for 30 US Treasury bonds with maturities over 6 months, including details such as code, maturity date, current price, yield to maturity, and coupon [30] 4. Macro Data Tracking - As of January 23, the 1 - year US Treasury yield was 3.5083%, down 2.66bps from the previous week; the 2 - year yield was 3.594%, up 0.8bps; the 5 - year yield was 3.8245%, up 0.93bps; the 10 - year yield was 4.2252%, up 0.23bps [35] 5. Macro News - The final annualized quarter - on - quarter growth rate of the US GDP in Q3 2025 was 4.4%, higher than the initial value. Trump reached an agreement framework on Greenland issues, and related tariffs will not take effect. Most economists expect the Fed to keep the benchmark interest rate unchanged this quarter. The US national debt increased by about $2.25 trillion in 2025. The IMF raised the economic growth forecasts for China and the world in 2026. The Bank of Japan kept the benchmark interest rate at 0.75%. South Korea's GDP grew 1% year - on - year in 2025. China's GDP in 2025 grew 5% year - on - year. The central bank governor said there is still room for reserve requirement ratio cuts and interest rate cuts this year. Three departments extended the tax incentives for innovative enterprise CDRs. The Ministry of Finance said the fiscal expenditure in 2026 will only increase. Six departments extended the tax incentives for community family services. Nine departments issued opinions to promote the high - quality development of the pharmaceutical retail industry. The shipment volume of Chinese foldable mobile phones increased 9.2% year - on - year in 2025. Housing prices in Chinese cities generally declined in December 2025. The extension proposal of "21 Vanke 02" was approved [34][35][36]

证券之星消息，迈得医疗发布业绩预告，预计2025年全年扣非后净利润盈利约5463.95万元。 公告中解释本次业绩变动的原因为： 迈得医疗2025年三季报显示，前三季度公司主营收入2.25亿元，同比上升2.31%；归母净利润883.67万 元，同比上升15.82%；扣非净利润-127.85万元，同比下降526.58%；其中2025年第三季度，公司单季度 主营收入8364.3万元，同比上升54.38%；单季度归母净利润279.16万元，同比上升224.07%；单季度扣 非净利润123.64万元，同比上升118.23%；负债率29.86%，投资收益16.76万元，财务费用-52.36万元， 毛利率40.19%。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 2025年度,公司整体营业收入实现大幅增长,主要系公司统筹推进生产计划有序落地,保障了产品有效交付, 并且坚持技术创新与工艺迭代双轮驱动,持续强化产品竞争力与市场影响力,血液净化类和药械组合类智 能装备业务发展良好,尤其得益于药械组合类医用耗材在终端市场展现出良好的需求增长态势,对应 ...